Recombinetics Inc., of St. Paul, Minn., focused on gene-editing solutions for human health and animal agriculture, said it completed a $34 million series A financing round. Proceeds will be used to accelerate new research and development and build out the business development, product marketing and management team to take advantage of licensing and co-development opportunities.